SEP. 3 (WED) - 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

• Name: Jinyong Kim

• Current Position & Affiliation: Clinical Assistant Professor, Samsung Medical

Center

• Country: Korea

## • Educational Background:

2000-2011 D.S. Whicholai Diology, University of Cambrilla at Deficien	2008-2011	B.S.	Microbial Biology, University of California at Berkeley
---	-----------	------	---

2013-2016 M.D. Seoul National University College of Medicine 2020-2023 Ph.D Medical Scientist Training Program (2020)

Department of Translational Medicine, Seoul National

University College of Medicine

## • Professional Experience:

2024-	Clinical Assistant Professor	Department of Hematology and Oncology,
		Samsung Medical Center
2022-2023	Clinical Assistant Professor	Department of Hematology and Oncology,
		Seoul National University Hospital
2021	Clinical Fellowship	Department of Hematology and Oncology,
		Seoul National University Hospital
2017-2020	Residency	Department of Internal Medicine,
		Seoul National University Hospital
2016	Internship	Seoul National University Hospital

## • Professional Organizations:

Member of KSMO (Korean Society of Medical Oncology) Member of KCSG (Korean Cancer Study Group) Member of IASLC (International Association for the Study of Lung Cancer Member of KALC (Korean Association for Lung Cancer)

## Main Scientific Publications:

- 1. Kim J, Kim J, Seo KH, Lee KH, Park YH, Lin CH, Lu YS, Ueno T, Yap YS, Wong FY, Tan VKM, Lim GH, Tan SM, Yeo W, Liu Q, Leung R, Naito Y, Li H, Lee HB, Han W, Im SA; Asian Breast Cancer Cooperative Group. Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study. ESMO Open. 2024 Oct 15;9(11):103732.
- 2. Koh J, Kim J, Woo GU, Yi H, Kwon SY, Seo J, Bae JM, Kim JH, Won JK, Ryu HS, Jeon YK, Lee DW, Kim M, Kim TY, Lee KH, Kim TY, Lee JS, Seong MW, Kim S, Lee S, Yun H, Song MG, Choi J, Kim JI, Im SA. Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience. Cancer Res Treat. 2024 Aug 21.
- 3. Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA. Mutations of TP53 and genes related to homologous recombination repair in



SEP. 3 (WED) - 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

- breast cancer with germline BRCA1/2 mutations. Hum Genomics. 2023 Jan 6;17(1):2.
- 4. **Joe S**, <u>Kim J</u>, Lee JY, Jeon J, Byeon I, Han SW, Ryoo SB, Park KJ, Cho S, Shim H, Bao Khanh Chu H, Kang J, Lee HS, Kim D, Kim YJ, Kim TY, Kim SY. Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea. *BMB Rep.* 2023 Aug 14:5951. Epub ahead of print.
- 5. <u>Kim J</u>, Jeong J, Lee CM, Lee DW, Kang CK, Choe PG, Kim NJ, Oh MD, Lee CH, Park WB, Lee KH, Im SA. Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer. *Front Immunol*. 2022 Nov 17;13:1028102.
- 6. <u>Kim J</u>, Chang E, Park SY, Lee DW, Kang CK, Choe PG, Kim NJ, Oh MD, Park WB, Lee KH, Im SA. Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment. *Oncologist*. 2022 Dec 9;27(12):e931-e937.
- 7. <u>Kim J</u>, Byun JM, Hong J, Koh Y, Shin DY, Kim I, Yoon SS, Park H, Bang SM. Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms. *Sci Rep.* 2021 Sep 8;11(1):17819.
- 8. <u>Kim J,</u> Byun JM, Hong J, Koh Y, Shin DY, Kim TM, Yoon SS, Park H, Kim I. Treatment outcomes and prognostic factors of patients with lymphoblastic lymphoma in East Asia. Medicine (Baltimore). 2024 Feb 16;103(7):e37100.
- 9. <u>Kim J</u>, Shin SD, Jeong S, Suh GJ, Kwak YH. Effect of prohibiting the use of Paraquat on pesticide-associated mortality. BMC Public Health. 2017 Nov 2;17(1):858. doi: 10.1186/s12889-017-4832-4. PMID: 29096617; PMCID: PMC5667494.

